{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-022200","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.477535+00:00","generated_at":"2026-05-15T08:09:45.745271+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keenova reports Q4 results above expectations but warns of potential debt defaults due to 10-K delay","bullets":["Q4 continuing ops net sales $543M; Acthar Gel $205.6M, XIAFLEX $156.5M; adjusted EBITDA $210-220M.","2026 guidance: net sales $1.94-2.00B, adjusted EBITDA $730-760M; pursuing NYSE listing in H2 2026.","Delay in 2025 10-K filing due to merger/spin-off accounting; will file by April 15, 2026.","Covenant defaults triggered under $1.48B term loan and $1.0B notes if audited statements not delivered within grace periods.","Exploring sale of Percocet opioid business (~$65M sales, $64M adjusted EBITDA in 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-022200","json":"https://secwatch.observer/filing/0001628280-26-022200.json","markdown":"https://secwatch.observer/filing/0001628280-26-022200.md","text":"https://secwatch.observer/filing/0001628280-26-022200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026022200/0001628280-26-022200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026022200/mnk-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:09:45.745271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc37c6ef9a22fccd4969770c8ec48229a062f969","claim":"Keenova Therapeutics plc reported the fourth quarter ended December 31, 2025 results: revenue $543.0 million.","evidence_excerpt":"Today at 8:00 a.m. ET Fourth Quarter 2025 Highlights 3 • Acthar Gel net sales of $205.6 million • XIAFLEX net sales of $156.5 million • Net sales from continuing operations of $543.0 million • Loss from continuing operations expected to be between $105.0 million and $115.0 million. • Adjusted EBITDA from continuing operations expected to be between $210.0 million and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026022200/0001628280-26-022200-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$543.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}